Trial Profile

A Phase II Study of PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
Indications Malignant melanoma
Focus Therapeutic Use

Most Recent Events

12 Jan 2023 Status changed from recruiting to completed, according to Results published in the European Journal of Cancer .
12 Jan 2023 Results published in the European Journal of Cancer
08 Jun 2021 Results assessing the safety and efficacy of camrelizumab in combination with apatinib in advanced treatment-naive acral melanoma pts presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com